Caricamento...
Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma
BACKGROUND: Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, −2 and −3, with a long half-life. Tivozanib has demonstrated clinical activity and acceptable tolerability in renal cell carcinoma (RCC). This phase Ib study determine...
Salvato in:
| Pubblicato in: | Eur J Cancer |
|---|---|
| Autori principali: | , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2013
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4666006/ https://ncbi.nlm.nih.gov/pubmed/23726267 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2013.04.019 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|